Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Vaxcyte, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 197
- +11 vs. Q1 2023
- Shares held
- 100.1M
- +16.0M (+19.0%) vs. Q1 2023
- Total value
- $5.00B
- +$1.84B (+58.5%) vs. Q1 2023
- New holders
- 37
- 106 more added
- Sold out
- 26
- 39 more reduced
2 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PCVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 331 | $9.71B |
| Q1 2026 | 336 | $9.44B |
| Q4 2025 | 295 | $6.81B |
| Q3 2025 | 285 | $5.09B |
| Q2 2025 | 294 | $4.80B |
| Q1 2025 | 315 | $5.88B |
| Q4 2024 | 323 | $11.5B |
| Q3 2024 | 329 | $15.6B |
| Q2 2024 | 265 | $9.26B |
| Q1 2024 | 251 | $8.13B |
| Q4 2023 | 223 | $6.47B |
| Q3 2023 | 202 | $5.17B |
| Q2 2023 | 197 | $5.00B |
| Q1 2023 | 188 | $3.15B |
| Q4 2022 | 198 | $3.91B |
| Q3 2022 | 126 | $1.36B |
| Q2 2022 | 106 | $1.12B |
| Q1 2022 | 88 | $1.20B |
| Q4 2021 | 87 | $1.06B |
| Q3 2021 | 78 | $1.10B |
| Q2 2021 | 75 | $972.7M |
| Q1 2021 | 74 | $869.2M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Vaxcyte, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 0 | $0 | 0.00% | −579,508−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −295,000−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −238,398−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −105,800−100.0% | Sold out |
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −90,000−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −50,626−100.0% | Sold out |
| Altium Capital Management LP | 0 | $0 | 0.00% | −43,000−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −39,500−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −30,308−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| Renaissance Capital LLC | 0 | $0 | 0.00% | −23,688−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −21,688−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −13,110−100.0% | Sold out |
| Candriam Luxembourg S.C.A. | 0 | $0 | 0.00% | −12,070−100.0% | Sold out |
| Seven Eight Capital, LP | 0 | $0 | 0.00% | −9,636−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −8,071−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −6,768−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| BIT Capital GmbH | 0 | $0 | 0.00% | −2,100−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −694−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −258−100.0% | Sold out |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −148−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −45−100.0% | Sold out |
| ETF Managers Group, LLC | – | – | – | – | Not filed |
| Harvest Group Wealth Management, LLC | – | – | – | – | Not filed |